| Rare essentials: drugs for rare diseases as essential medicines P Stolk, MJC Willemen, HGM Leufkens Bulletin of the World Health Organization 84 (9), 745-751, 2006 | 178 | 2006 |
| Meta-analysis of placebo rates in major depressive disorder trials P Stolk, MJ Berg, MEH Hemels, TR Einarson Annals of Pharmacotherapy 37 (12), 1891-1899, 2003 | 86 | 2003 |
| Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder P Stolk, PC Souverein, I Wilting, HGM Leufkens, DF Klein, SI Rapoport, ... Prostaglandins, leukotrienes and essential fatty acids 82 (1), 9-14, 2010 | 81 | 2010 |
| The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: observations and recommendations K Klein, P Stolk, ML De Bruin, HGM Leufkens, DJA Crommelin, ... European Journal of Pharmaceutical Sciences 133, 228-235, 2019 | 57 | 2019 |
| How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers’ views G Tafuri, P Stolk, F Trotta, M Putzeist, HG Leufkens, RO Laing, ... Annals of oncology 25 (1), 265-269, 2014 | 52 | 2014 |
| Priority medicines for Europe and the world update 2013 report W Kaplan, V Wirtz, A Mantel, PSU Béatrice Methodology 2 (7), 99-102, 2013 | 52 | 2013 |
| The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review M Mitratza, BM Goodale, A Shagadatova, V Kovacevic, J Van de Wijgert, ... The Lancet Digital Health 4 (5), e370-e383, 2022 | 48 | 2022 |
| Traceability of biologics in The Netherlands: an analysis of information-recording systems in clinical practice and spontaneous ADR reports K Klein, JHG Scholl, NS Vermeer, AW Broekmans, EP Van Puijenbroek, ... Drug Safety 39, 185-192, 2016 | 40 | 2016 |
| The use of driving impairing medicines: a European survey S Ravera, SA Hummel, P Stolk, RE Heerdink, LTW de Jong–van den Berg, ... European journal of clinical pharmacology 65, 1139-1147, 2009 | 39 | 2009 |
| Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice P Stolk, BLG Van Wijk, HGM Leufkens, ER Heerdink Journal of Human Hypertension 20 (12), 917-922, 2006 | 38 | 2006 |
| Challenges and opportunities for the traceability of (biological) medicinal products K Klein, P Stolk Drug Safety 41, 911-918, 2018 | 37 | 2018 |
| The future of drug development: the paradigm shift towards systems therapeutics M Danhof, K Klein, P Stolk, M Aitken, H Leufkens Drug discovery today 23 (12), 1990-1995, 2018 | 32 | 2018 |
| Fate of abstracts presented at five International Conferences on Pharmacoepidemiology (ICPE): 1995–1999 P Stolk, ACG Egberts, HGM Leufkens pharmacoepidemiology and drug safety 11 (2), 105-111, 2002 | 29 | 2002 |
| FDA facilitated regulatory pathways: visualizing their characteristics, development, and authorization timelines L Liberti, M Bujar, A Breckenridge, J Hoekman, N McAuslane, P Stolk, ... Frontiers in pharmacology 8, 161, 2017 | 27 | 2017 |
| Pharmaceutical sciences in 2020 D Crommelin, P Stolk, L Besançon, V Shah, K Midha, H Leufkens Nature Reviews Drug Discovery 9 (2), 99, 2010 | 27 | 2010 |
| Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities L Liberti, A Breckenridge, J Hoekman, H Leufkens, M Lumpkin, ... Journal of Public Health Policy 37, 315-333, 2016 | 25 | 2016 |
| No difference in between-country variability in use of newly approved orphan and non-orphan medicinal products-a pilot study P Stolk, HE Heemstra, HGM Leufkens, B Bloechl-Daum, ER Heerdink Orphanet Journal of Rare Diseases 4, 1-7, 2009 | 24 | 2009 |
| When more is less: an exploratory study of the precautionary reporting bias and its impact on safety signal detection K Klein, JHG Scholl, ML De Bruin, EP van Puijenbroek, HGM Leufkens, ... Clinical Pharmacology & Therapeutics 103 (2), 296-303, 2018 | 23 | 2018 |
| Priority medicines for Europe and the World 2013 update. 2013 W Kaplan, VJ Wirtz, A Mantel-Teeuwisse, P Stolk, B Duthey, R Laing WHO Library, 2018 | 21 | 2018 |
| Measuring the value of public–private partnerships in the pharmaceutical sciences TR Denee, A Sneekes, P Stolk, A Juliens, JAM Raaijmakers, M Goldman, ... Nature Reviews Drug Discovery 11 (5), 419-419, 2012 | 19 | 2012 |
